- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01056731
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)
February 21, 2017 updated by: Novartis
A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration.
The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s), followed by a 16-week open-label active treatment period.
Patients will be evaluated every 4 weeks during period 2. Treatment will start with Aliskiren 150 mg with dose titration to Aliskiren 300 mg, and addition of HCTZ 12,5 mg and 25 if control of BP is not achieved (< 140/90 mmHg or 130/ 80 mmHg in diabetics patients).
All patients who have reached their BP target will be considered as having met the primary endpoint and this visit will be considered as the final visit.
Study Overview
Study Type
Interventional
Enrollment (Actual)
253
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bolíva, Venezuela
- Investigative Site
-
Carabobo, Venezuela
- Investigative Site
-
Caracas, Venezuela
- Investigative Site
-
Edo Zulia, Venezuela
- Investigative Site
-
Estado Monagas, Venezuela
- Investigative Site
-
Falcón, Venezuela
- Investigative Site
-
Maracaibo Estado Zulia, Venezuela
- Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatients, with essential hypertension, stage I-II, naïve or not controlled with monotherapy.
Exclusion Criteria:
- BP> 180/110 mmHg
- Pregnant or nursing women
- Hypertensive encephalopathy or cerebrovascular accident, transient ischemic - cerebral attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention within 6 month
- K <3.5 mEq/L or ≥ 5 mEq/L
- Renal impairment
- Hypersensitivity to HCTZ or Aliskiren or angioedema due to ACE-I or ARB
- Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Aliskiren and Aliskiren_HCTZ
aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
|
Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients in whom BP control was achieved at the study end point
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients in whom BP control was reached before the addition of HCTZ (ie, at the pre-HCTZ end point
Time Frame: 8 weeks
|
8 weeks
|
Percentage of patients achieving overall BP, DBP, an SBP control rate at week 4, 8, 12 and 16.
Time Frame: 16 weeks
|
16 weeks
|
Change in msSPA and msDBP from baseline to different time points
Time Frame: 4,8,12 and 16 weeks
|
4,8,12 and 16 weeks
|
Safety of Aliskiren therapy at different time points
Time Frame: 4,8,12 and 16 weeks
|
4,8,12 and 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (ACTUAL)
October 1, 2011
Study Completion (ACTUAL)
October 1, 2011
Study Registration Dates
First Submitted
January 25, 2010
First Submitted That Met QC Criteria
January 25, 2010
First Posted (ESTIMATE)
January 26, 2010
Study Record Updates
Last Update Posted (ACTUAL)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 21, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSPP100AVE01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High Blood Pressure
-
GE HealthcareTerminatedBlood Pressure (Low, Normal, High)United States
-
Dow University of Health SciencesCompletedCognitive Change | Blood Pressure | Blood Glucose, HighPakistan
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
University of BolognaCompletedHigh-Normal Blood PressureItaly
-
Medical University of WarsawCompletedArterial Calcification | Aortic Stiffness | High Blood Pressure (& [Essential Hypertension])Poland
-
Regina Elena Cancer InstituteCompletedMechanical Ventilation Pressure HighItaly
-
University of Novi SadRecruitingMechanical Ventilation Pressure HighSerbia
-
Joseph D. TobiasNot yet recruitingSurgery | Mechanical Ventilation Pressure HighUnited States
-
HeadSense MedicalUnknownPresence of High Intracranial PressureUnited States, Germany
Clinical Trials on Aliskiren and HCTZ
-
Vanderbilt University Medical CenterCompletedHigh Blood PressureUnited States
-
NovartisCompleted
-
NovartisCompletedHypertensionUnited States, Germany
-
Novartis PharmaceuticalsTerminatedNon-diabetic NephropathyNetherlands
-
NovartisCompletedHypertensionSwitzerland, Italy, Argentina, Germany, Turkey, United States, Ecuador, Guatemala
-
Novartis PharmaceuticalsTerminatedCardiovascular EventsColombia, India, South Africa, Canada, Spain, Hungary, United States, Germany, Ireland, Argentina, Philippines, Brazil, Sweden, Malaysia, Chile, Israel, Czech Republic, Netherlands
-
NovartisCompleted
-
NovartisCompleted
-
Vanderbilt University Medical CenterCompletedGlucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus | Endocrine System DiseasesUnited States
-
NovartisCompletedHypertensionSlovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland